The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHalma Regulatory News (HLMA)

Share Price Information for Halma (HLMA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2,219.00
Bid: 2,216.00
Ask: 2,218.00
Change: 41.00 (1.88%)
Spread: 2.00 (0.09%)
Open: 2,196.00
High: 2,223.00
Low: 2,182.00
Prev. Close: 2,178.00
HLMA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

21 Sep 2023 07:00

RNS Number : 1335N
Halma PLC
21 September 2023
 

Trading update

 

Halma, the global group of life-saving technology companies focused on growing a safer, cleaner and healthier future, today releases its scheduled trading update ahead of its half year end on 30 September 2023.

Further progress in the first half and unchanged guidance for the full year

We have made further progress in the first half of this financial year despite varied market conditions. Our guidance for the full year to March 2024, for good organic constant currency1 revenue growth and Return on Sales2 of approximately 20%, is unchanged from that given in our results announcement in June3.

We expect the balance of revenue and Adjusted profit before taxation4 between the first and second half of this financial year to be in line with pre-COVID historical averages5.

Accordingly, in the first half of the year, we expect good organic constant currency1 revenue growth against a strong comparative period last year, and Return on Sales2 towards the lower end of our target range.

Our cash performance is enabling continued investment, both organically and in acquisitions, to expand our opportunities for growth over the medium to longer term.

Continued progress in varied market conditions

We continue to benefit from the strength and relevance of our purpose, the agility and entrepreneurialism which we derive from our Sustainable Growth Model, and the diversity and global reach of our portfolio. These are enabling us to deliver continued progress in varied market conditions.

Group order intake is ahead of the comparable period last year and close to revenue in the year to date. Order intake in the Safety and Environmental & Analysis sectors is in line with revenue; the Healthcare sector has experienced slower order intake, with the effects of recovery from post-COVID disruptions resulting in destocking by OEM customers and budgetary pressures at healthcare providers.

Revenue by sector on an organic constant currency1 basis reflects order book trends, with stronger growth in the Safety and Environmental & Analysis sectors, and similar revenue to the first half of last year in the Healthcare sector. All sectors will benefit from recent acquisitions.

Return on Sales2 in the Safety and Healthcare sectors is expected to be higher in the first half of the year, relative to the comparable period last year. The Environmental & Analysis sector's first half Return on Sales2 is expected to be lower due to mix effects.

By geography, the USA and Mainland Europe have delivered strong organic constant currency1 revenue growth, while the UK has grown modestly; together, these account for nearly 80% of Group revenue. Organic constant currency1 revenue performance in Asia Pacific was negative, reflecting declines in China, partially offset by a strong performance in Australasia.

The appreciation of Sterling is having a negative currency translation effect on the Group's results; we expect this effect to continue in the second half of the year6.

Further progress in M&A; healthy acquisition pipeline

Following a record acquisition spend in the 2023 financial year, with seven acquisitions completed for a maximum total consideration of £397m, we made three acquisitions in the first half of this financial year for a maximum total consideration of £80m. We have a healthy acquisition pipeline across all three sectors.

We continue to actively manage our portfolio of global businesses to ensure that it continues to deliver strong growth and returns and is aligned with our purpose of growing a safer, cleaner, healthier future for everyone, every day. We made one small disposal, of our 70% stake in FireMate Software Pty. Ltd. (FireMate), for a total consideration of AUD8.4m (£4.3m), of which AUD2.1m (£1.1m) is deferred. Halma will retain FireMate's Nimbus digital solution that enables remote connectivity for fire and evacuation systems.

In our Environmental & Analysis sector, we acquired Visual Imaging Resources LLC as a bolt-on to Minicam in April and Sewertronics Sp. Z o.o. as a standalone company in May; details of these acquisitions were previously reported in our Full Year 2023 results released in June. In August, we acquired Lazer Safe Pty. Ltd., an Australia-based designer and manufacturer of safety solutions for industrial press brake applications, for AUD45m (approximately £23m) on a cash and debt free basis, as a standalone company within the Safety sector.

Half Year Results

The results for the half year ending 30 September 2023 will be released on Thursday 16 November 2023.

For further information, please contact:

Halma plc

Marc Ronchetti, Group Chief Executive +44 (0)1494 721111

Steve Gunning, Chief Financial Officer

Charles King, Head of Investor Relations +44 (0) 7776 685948

Clayton Hirst, Director of Corporate Affairs +44 (0) 7384 796 013

MHP Communications

Oliver Hughes / Rachel Farrington / Ollie Hoare +44 (0)20 3128 8622 / 8613 / 8276

Notes:

1. Organic constant currency measures exclude the effect of movements in foreign exchange rates on the translation of revenue and profit into Sterling, as well as acquisitions in the year following completion and disposals.

2. Return on Sales is defined as Adjusted profit before taxation4 from continuing operations expressed as a percentage of revenue from continuing operations.

3. The following guidance was given in our Full Year 2023 results announcement in June 2023: "Based on current market conditions, we expect to deliver good organic constant currency1 revenue growth in the year ahead, and Return on Sales2 to increase to approximately 20%."

4. Adjusted profit before taxation is before amortisation and impairment of acquired intangible assets, acquisition items, and profit or loss on disposal of businesses.

5. In the five financial years from 2016/17 to 2020/21, Halma delivered on average 48% of its annual revenue in the first half of the year, and 45% of its Adjusted profit before taxation4.

6. Sterling has strengthened in the year relative to many currencies, including the US Dollar and Euro. If current exchange rates continue throughout the rest of the current financial year, the currency translation impact on the Group's results is expected to be negative. Based on exchange rates of Sterling/US Dollar 1:1.26 and Sterling/Euro 1:1.17, we would expect approximately a £55m negative revenue effect and approximately a £13m negative profit effect in the 2024 financial year, compared to the 2023 financial year, of which approximately 30% would occur in the first half of the financial year.

7. This Trading Update is based upon unaudited management accounts information. Forward-looking statements have been made by the Directors in good faith using information available up until the date that they approved this statement. Forward-looking statements should be regarded with caution because of the inherent uncertainties in economic trends and business risks.

8. A copy of this announcement, together with other information about Halma, may be viewed on its website at www.halma.com.

About Halma

Halma is a global group of life-saving technology companies, focused on growing a safer, cleaner, healthier future for everyone, every day. Its purpose defines the three broad market areas where it operates:

· Safety - Protecting people's safety and the environment as populations grow, and enhancing worker safety.

· Environment - Addressing the impacts of climate change, pollution and waste, protecting life-critical resources and supporting scientific research.

· Health - Meeting the increasing demand for better healthcare as chronic illness rises, driven by growing and ageing populations and lifestyle changes.

Halma employs over 8,000 people in more than 20 countries, with major operations in the UK, Mainland Europe, the USA and Asia Pacific. Halma is listed on the London Stock Exchange (LON: HLMA) and is a constituent of the FTSE 100 index.

Halma has been named as one of Britain's Most Admired Companies for the past five years.

For more information www.halma.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSESFUSEDSEDU
Date   Source Headline
19th Mar 20243:53 pmRNSDirector/PDMR Shareholding
14th Mar 20247:00 amRNSTrading Update
4th Mar 20247:00 amRNSAcquisition
21st Feb 20244:17 pmRNSDirector/PDMR Shareholding
30th Jan 20247:00 amRNSDirectorate Change
30th Nov 20235:28 pmRNSPDMR Shareholding
22nd Nov 20234:36 pmRNSDirector Declaration
20th Nov 20237:00 amRNSAcquisition
16th Nov 20237:00 amRNSHalf Year Results
25th Oct 20237:00 amRNSAcquisitions
3rd Oct 202310:50 amRNSDirector/PDMR Shareholding
27th Sep 202312:28 pmRNSHolding(s) in Company
25th Sep 20231:00 pmRNSDirector/PDMR Shareholding
21st Sep 20237:00 amRNSTrading Update
4th Aug 20237:00 amRNSAcquisition
31st Jul 20233:00 pmRNSDirector/PDMR Shareholding
24th Jul 20239:00 amRNSDirectorate Change
20th Jul 20233:51 pmRNSResult of AGM
30th Jun 20239:00 amRNSDirector/PDMR Shareholding
28th Jun 20233:00 pmRNSDirector/PDMR Shareholding
22nd Jun 20233:58 pmRNSAnnual Financial Report
15th Jun 20237:00 amRNSFull Year Results
30th May 20237:11 amRNSDirector Declaration
12th May 20238:00 amRNSCompletion of acquisition
5th May 20237:00 amRNSAcquisition
28th Mar 20237:00 amRNSAcquisition
16th Mar 20237:00 amRNSTrading update
1st Mar 20233:39 pmRNSDirector/PDMR Shareholding
1st Feb 20237:00 amRNSAcquisition
12th Jan 20237:00 amRNS2022 AGM – Voting Results Update Statement
29th Nov 202212:42 pmRNSDirector/PDMR Shareholding
17th Nov 20227:00 amRNSHalf Year Results
11th Nov 20227:00 amRNSHalma appoints new Chief Financial Officer
6th Oct 20227:00 amRNSAcquisition
3rd Oct 20224:38 pmRNSDirector/PDMR Shareholding
3rd Oct 20227:00 amRNSAcquisition
22nd Sep 20227:00 amRNSTrading Statement
28th Jul 20223:01 pmRNSDirector/PDMR Shareholding
21st Jul 20223:33 pmRNSResult of AGM
4th Jul 20223:38 pmRNSDirector/PDMR Shareholding
29th Jun 20229:54 amRNSDirector/PDMR Shareholding
23rd Jun 20225:50 pmRNSAnnual Financial Report
17th Jun 20224:41 pmRNSDirector/PDMR Shareholding
16th Jun 20227:01 amRNSGroup Chief Executive succession
16th Jun 20227:00 amRNSFinal Results
14th Apr 20227:00 amRNSAcquisition
7th Apr 20227:00 amRNSSite Visit
28th Mar 20221:59 pmRNSDirector/PDMR Shareholding
23rd Mar 20227:00 amRNSTrading update
21st Feb 20227:00 amRNSAcquisition

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.